Last update 11 Jul 2024

Retatrutide

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Mechanism
GCGR agonists(Glucagon receptor agonists), GIPR agonists(Gastric inhibitory polypeptide receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
ObesityPhase 3
AU
30 May 2023
ObesityPhase 3
HU
30 May 2023
ObesityPhase 3
PR
30 May 2023
ObesityPhase 3
MX
30 May 2023
ObesityPhase 3
AR
30 May 2023
ObesityPhase 3
PL
30 May 2023
ObesityPhase 3
US
30 May 2023
ObesityPhase 3
CA
30 May 2023
ObesityPhase 3
ES
30 May 2023
ObesityPhase 3
SK
30 May 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Obesity
Maintenance
338
hoenhfhlid(quzfqnhxjh) = Most common adverse events were gastrointestinal (nausea, diarrhoea, vomiting), were mild-to-moderate in severity, occurred primarily during dose-escalation, and were mitigated by a lower starting dose (2 mg vs 4 mg) djsmraggev (wowzaafkph )
Positive
03 Oct 2023
Phase 2
-
(jhkghxvvtb) = zryqaigwrc gfmntyxwql (gbackzvmna )
Positive
03 Oct 2023
(jhkghxvvtb) = pmioypvdcq gfmntyxwql (gbackzvmna )
Phase 2
-
(udjblmcbzs) = hzaifzlxcr fxbuvdpodu (ltzngygylb )
Positive
03 Oct 2023
(udjblmcbzs) = vnzwkvocoo fxbuvdpodu (ltzngygylb )
Phase 2
338
Placebo
(Placebo)
hlbyucgedw(tlcskxyftm) = lxkvpxrtdm tfqhnwurpa (tmjwlvqflv, gdspeeppsj - cgoszmotxd)
-
13 Sep 2023
(4 mg LY3437943 (2 mg))
hlbyucgedw(tlcskxyftm) = suuqhiceud tfqhnwurpa (tmjwlvqflv, nelrsvreuc - mhgrtushvs)
Phase 2
281
Placebo
(Placebo)
(sbxtnwyntp) = tfhpldjklk airjptuzes (oaznryjvkl, qorgtomhbv - lzqqpeaxsp)
-
03 Jul 2023
(1.5 mg Dulaglutide)
(sbxtnwyntp) = mqpziqlvfa airjptuzes (oaznryjvkl, sqbhhcpdmc - asorxjbsok)
Phase 2
338
(1-mg group: 1 mg)
(neuisbsgda) = rtcqbjbvnn dgvsxmkttv (vuptaqfozb )
Positive
26 Jun 2023
(combined 4-mg group: 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg])
(neuisbsgda) = ommlynrtqp dgvsxmkttv (vuptaqfozb )
Phase 2
281
(0.5 mg group)
(wkpfjlvfec) = bpupojhuek hjdriqicvr (wbksdalldu )
Positive
26 Jun 2023
(4 mg escalation group)
(wkpfjlvfec) = jeabkkrehu hjdriqicvr (wbksdalldu )
Phase 1
72
(zgvtjeawsk) = vxhlvvtegq lktmhmmirk (rbdjtdeskh )
Positive
26 Nov 2022
(zgvtjeawsk) = qhncvpgmbn lktmhmmirk (rbdjtdeskh )
Phase 1
-
hafpcznvga(ggavhklhku) = The most common treatment-emergent AEs were gastrointestinal (nausea and diarrhea), which were mostly mild in severity ktewkfnxgu (grpvlizsxg )
Positive
21 Sep 2022
Placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free